|
| ||
|
|
||
Cholangiocellular Carcinoma (cholangiocellular + carcinoma)
Selected AbstractsContrast media-enhanced power Doppler sonography for evaluation of hemangiomas and malignant tumors in the liverJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Issue 1 2003AYDIN KARABACAKOGLU Abstract Aim: To evaluate the characterization of liver hemangiomas and malignant tumors using power Doppler sonography before and after intravenous injection of a sonocontrast agent. Methods: Forty-five patients with 57 liver tumors (22 hemangiomas, 24 metastases, 10 hepatocellular carcinomas (HCC) and one cholangiocellular carcinoma) were examined prospectively. The distribution (peripheral, central, mosaic) and extent (none, minimal, moderate and strong) of intratumoral flow pattern in each sonographic examination was subjectively classified. Results: The administration of the sonocontrast agent by bolus injection caused enhancement to gradually increase up to 2 min and lasted for 4,5 min. After injection of contrast agent, flow signals appeared or increased in 34 tumors. No signal enhancement was observed in 18 hemangiomas, four metastases and one HCC. The sensitivity and specificity of intratumoral vascularity for the detection of malignant liver tumors was 37.1 and 90.9% for unenhanced power Doppler sonography, and 85.7 and 81.8% for contrast-enhanced power Doppler sonography, respectively. Conclusion: Contrast-enhanced power Doppler sonography is superior to unenhanced power Doppler sonography in the demonstration of malignant tumor vascularity, and is helpful in differentiating between hemangiomas and malignant liver tumors. A specific flow pattern within the tumor is not established in primary and metastatic malignant tumors with contrast-enhanced power Doppler sonography. © 2003 Blackwell Publishing Asia Pty Ltd [source] The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation studyALIMENTARY PHARMACOLOGY & THERAPEUTICS, Issue 9 2004A. Kerber Summary Background :,Malignant cells characteristically possess high levels of plasminogen activator, which induce local fibrinolysis. The DR-70 immunoassay is a newly developed test, which quantifies fibrin degradation products in serum by a proprietary antibody. Aim :,To evaluate the DR-70 immunoassay as a detection assay for the presence of gastrointestinal cancers. Methods :,We prospectively collected blood sera of 85 patients with histologically proven tumour and 100 healthy blood donors. Ten microlitres of the sera was used for the DR-70 immunoassay. Nineteen patients had a hepatocellular and 10 cholangiocellular carcinoma, 13 cancer of the pancreas, 30 colorectal cancer, 10 stomach cancer and three cancer of the oesophagus. Results :,Receiver,operator curve analysis revealed <0.7 ,g/mL as the best cut-off value to distinguish between patients with cancer and healthy controls. Using this cut-off value, the DR-70 immunoassay showed a good clinical performance with a sensitivity of 91% and a specificity of 93%. Patients with advanced tumour spread showed significantly higher DR-70 values than those with early-stage tumours (P < 0.0003). Conclusion :,The DR-70 immunoassay reliably differs between cancer patients and healthy controls. Therefore, it promises to become a useful test for the detection of cancer in clinical practice. [source] Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinomaCANCER, Issue 2 2002Shiro Miwa M.D. Abstract BACKGROUND Matrix metalloproteinase-7 (MMP-7) recently has been reported to play a role in tumor cell invasion. The objective of the current study was to examine the expression of MMP-7 in patients with cholangiocellular carcinoma. METHODS Twenty-six patients underwent resection of cholangiocellular carcinoma, leaving no macroscopic evidence of residual tumor. Immunostaining was performed to evaluate the relation between MMP-7 expression and clinicopathologic features and patient prognosis. The immunostaining pattern of the tumor cells for MMP-7 was classified as negative (,) (n = 9), positive (+) (n = 11), or strongly positive (++) (n = 6). Western blot analysis was performed to investigate the expression of active or latent forms in cancerous and noncancerous lesions in four patients. RESULTS The survival rates in patients with MMP-7 expression judged to be (,), (+), and (++) were 75%, 80%, and 0%, respectively, at 1 year, and 47%, 24%, and 0%, respectively, at 3 years. The survival rate of MMP-7 (++) patients was significantly lower than that of MMP-7 (+) patients (P = 0.003) and MMP (,) patients (P = 0.008). At last follow-up, 3 patients in the MMP-7 (,) group had survived for > 5 years. Western blot analysis demonstrated that there were two types of cholangiocellular carcinoma: those producing both latent and active MMP-7 and those producing only the latent form. CONCLUSIONS Although the results of the current study are based on a small number of patients, they suggest that MMP-7 expression is a significant prognostic factor in patients with cholangiocellular carcinoma and that cholangiocellular carcinoma demonstrating strongly positive expression of MMP-7 on immunostaining may have a higher malignant potential compared with that showing negative or positive expression of MMP-7. Cancer 2002;94:428,34. © 2002 American Cancer Society. [source] Effect of tumour necrosis factor-, and irradiation alone or in combination on the viability of hepatocellular and biliary adenocarcinoma cell lines in vitroLIVER INTERNATIONAL, Issue 6 2009Blendi Qesaraku Abstract Background: Tumour necrosis factor , (TNF-,) may exhibit antitumoral activity and can influence the reaction of both tumour and normal tissue to radiation. Aims: To test the effect of TNF-, and/or irradiation on hepatocellular (HepG2, Hep3B, Sk-Hep1, HuH7) and cholangiocellular (Sk-chA1, Mz-chA1) tumour cell lines. Methods: Colony formation, apoptosis analysis and trypan blue exclusion were used to assess cell viability. Doses of radiation (2,25 Gy) and TNF-, (100,50 000 U) as well as their respective sequencing were varied (24 and 12 h before and 6 h after). The expression of TNF-, and TNF receptors 1/2 was determined using real-time polymerase chain reaction and I,B, protein expression was detected by Western blot. Results: Sole irradiation induced a reduction in colony formation in all cell lines and sole TNF-, in HepG2 and Sk-chA1 cells only. No difference in apoptosis induction after TNF-, or irradiation was observed. Cellular death induced by the combination of TNF-, and radiation was not superior to the use of any of the two agents alone. All cell lines revealed that radiation induced upregulation of TNF-, whereas the extent of TNF receptor-specific transcription did not change. Furthermore, radiation-induced changes in I,B, expression were not detectable. Conclusions: Our data suggest that both TNF-, and radiation may be treatment options for hepatocellular and cholangiocellular carcinomas. Because TNF-, and radiation do not interact in terms of radiosensitization, anti-TNF-, treatment may have the potential to protect against hepatocellular injury after abdominal irradiation. However, further in vivo studies are needed to confirm that anti-TNF-, treatment does not compromise tumour control and actually attenuates radiation-induced liver injury. [source] | ||||||||||